Developing Small Molecule Therapeutics for Inducing Abnormal Cell Apoptosis and Mitigating Chromosomal Aberrations

Abstract

Background and Objectives: Allicin which is the principal bioactive organosulfur compound of Allium sativum, has witnessed a transition from ethnopharmacological use to modern-day precision medicine. For 5,000 years it has been used as a medicine for inflammatory and reproductive diseases, yet there remains an enormous translational gap between mechanistic evidence from laboratories and use in the clinic. This study assessed the effectiveness of MEnera, an FDA-registered Allicin-based Small-Molecule Therapeutic, in decreasing genomic instability and chromosomal abnormalities. Develop a link between the molecular genoprotective properties of Allicin in wild garlic and the clinical therapeutic effects in reproductive and cancer diseases. Mechanism of Action: Allicin's primary bioactive mechanisms were clinically proven to be an apoptosis-inducing mechanism and a DNA-stabilising mechanism. Allicin induces mitochondrial depolarization and caspase activation that contribute to programmed cell death in malignant and hyperplastic tissues. In particular, the compound opens the mitochondrial permeability transition pore (mPTP) resulting in an apoptosis rate of 50% in malignant cell lines. At the same time, the compound is genoprotective in healthy tissues by activating the NRF2 cellular defense pathway. This mechanism stimulates the movement of NRF2 into the nucleus, leading to a tripling of DNA repair enzymes and antioxidant genes important for keeping up the normal quality of oocyte and protecting from oxidative damage. Methods: The MEnera trial was a controlled clinical trial, stratified by age, with 80 female participants with reproductive disorders, such as Polycystic Ovary Syndrome (PCOS), endometriosis, menorrhagia, and others. To detect large effect sizes with a power of 80% and assurance level of p=0.05, the trial has used a sample size of n=80. The 40 participants were divided into two groups, A (21-40 years) and B (41-65 years) and C group was given placebo (n=40). Over a 90-day period, the treatment groups received stabilized Allicin-based small-molecule therapy (150 mg) twice daily. The study’s primary ends included menstrual regularity, the biomarker (8- OHdG) in follicular fluid and genomic stability, as assessed by micronuclei in PBMCs. Results: Based on the age at which they were treated, the trial had a good outcome. In Group A, pregnancy was achieved in 15% of the cases which was associated with 40% lowering of oxidative stress markers in follicular fluid. On the other hand, Group B had a pregnancy rate of 5% indicating that Allicin is not effective in combating severe chromosomal abnormality due to age. However, both treatment groups had an overall reduction of 80%, and menorrhagia showed an overall reduction of 85%. The placebo group experienced an enhancement of fewer than 10%. Confirmation given by the statistics showed that treated subjects were 4.2 times (95% CI: 2.8–6.1) less risky as compared to controls (p<0.001). Conclusion: According to the MEnera trial, research conveys that Allicin restores hormonal pulsatility and treats endometrial hyperplasia, with the highest immuno-genomic stabilizing potential seen in younger subjects. Allied compounds can bridge the gap between ethnopharmacology and evidence-based medicine for fertility preservation and oncological protection because of their low toxicity.

Keywords

Allicin, Allium sativum, Genomic stability, Genoprotection, Apoptosis, NRF2 pathway, Mitochondrial permeability transition pore (mPTP), Reproductive disorders, Polycystic Ovary Syndrome, Endometriosis, Oxidative stress, 8-OHdG, Micronuclei assay, Precision medicine, Small-molecule therapeutics

Introduction

The use of ethnopharmacologically derived components in medicine is increasing and tips the balance of possibilities for fusing traditional with modern molecular medicine. Allicin, an organosulfur compound predominantly occurring in garlic (Allium sativum), is an instance of such a complex union. For years Allium sativum has been used by different cultures to treat infection, hormone imbalance and other inflammatory conditions.  These traditional applications have been validated by modern empirical evidence which shows that Allicin displays antimicrobial, anti-inflammatory and antineoplastic properties [1].

Developing treatment options that target cancerous cells without adversely impacting fertility is one of the biggest hurdles in modern cancer care. The impediment of apoptosis enables tumor cells to escape programmed cell death and genomic instability, which usually develop chemoresistance [2]. According to [3], the instability resulting from oxidative DNA damage and poor repair capacity  may lead towards chromosomal aberrations, which in turn contribute to infertility and repeated loss of pregnancy. Having a condition such as PCOS or endometriosis often results in increased oxidative stress biomarkers that greatly damage oocyte viability and endometrial function [4].

Allicin has a double mechanism of action: it kills off diseased cells by inducing apoptosis while protecting normal tissue by trapping free radicals and activating the NRF2 pathway.  By activating this, DNA repair takes place which has been demonstrated to reduce 40–60% chromosomal aberrations in preclinical models [5]. Within the precision medicine context, Allicin has been synthesised into a stabilized small-molecule therapeutic MEnera, an FDA-registered drug derived from Allicin-producing stabilized phytochemical extraction [4]. Unlike their monoclonal antibodies counterpart to high molecular weight biological agents, MEnera draws on being a small molecule and therefore lower molecular weight therapeutic agent, which allows it to cross cell membranes, and also provides and acts at the site of disease [6].

1.1 The Research Gap

There is a huge translational gap that exists despite well-documented mechanistic benefits. Currently, there is no comprehensive framework associating a molecular genoprotective evidence base with a clinical therapeutic outcome for reproductive and oncological pathologies. Existing preclinical studies indicate that the reduction of micronuclei by Allicin has been successfully demonstrated in the laboratory models and its clinical translation is lacking. Bolstering the knowledge in the MEnera clinical study, the clinical findings were linked with molecular findings with the aim of recognizing how the genoprotective ability of Allicin can be changed in small molecule therapeutic designs.

2. LITERATURE REVIEW: CRITICAL APPRAISAL OF EVIDENCE

The use of Allium sativum formulations for therapy continues to be a matter of controversy in the medical literature, given the varying results in human studies [1, 2]. For a long time, traditional medicine has recommended garlic for treating gynecological and inflammatory diseases. However, the failure of the contemporary clinical replication can be mainly due of the numerous chemical and metabolic variables affecting the stability of Allicin, the active bio compound.[1]

2.1 Historical and Conventional Foundations

Over 5000 years ago garlic (Allium sativum) became part of the holistic medicine systems and it has cultural regard. Used medicinally by several cultures, Allicin has a rich cultural history [4]. Ancient Sanskrit texts like the Charaka Samhita classify garlic as one that strengthens the reproductive tissues (Shukra Dhatu) and is anti-menopausal (moderates excess menses) [4]. Under this umbrella Ayurveda describes Allicin as a Rasayana rejuvenating herb used to treat menstrual and dysmenorrhea and speed recovery after childbirth [3]

In a similar manner, Traditional Chinese Medicine makes use of Da Suan, also known as garlic, which is considered as a “heating plant”.  This makes it effective in destroying cold and dampness which results in an increase in the flow of liver as well as uterine Qi. TCM makes use of this herb in the treatment of amenorrhea as well as fibroids and leukorrhea.  This is also supported by historical accounts from Greece, Rome, and Persia [4]. Hippocrates stated that it can treat infection of the uterus. Romans used wines of Allicin to get the menses moving in amenorrheic patients [3]. These uses were based on the empirical demonstration that Allicin could refine blood and regulate uterine contractility, which was later credited to its Reactive Oxygen Species (ROS) scavenging skills and its anti-inflammatory properties [3, 5].

2.2 Critical Appraisal of Contradictory Clinical Outcomes

The clinical outcomes of garlic trials have been noted to be highly inconsistent as per critical appraisal of current literature 1, 2 while this is believed to possess a historical pedigree. The MEnera trial reported an 80% reduction in symptoms, but other large-scale garlic trials have not shown statistical significance [1, 6]. Most of these contradictions are conspired by these.

• Chemical Instability: Due to its unstable nature, Allicin shows a  physiological half-life of less than 60 minutes in human blood.  In many cases when using non-stabilised powders, trials fail because the compound degrades to less active sulphur compounds before the compound levels reach therapeutic thresholds [2].
• Bioavailability Barriers: When you manage crude garlic in your mouth, you lead to lower systemic (less than 5%) availability because gastric metabolism acts fast and inactivation by gastric enzymes [1, 2].
• Standardization Deficiencies: The lack of standardization of the measurement of “Allicin-potential” globally produces varying doses in clinical studies [1].

Based on this study, MEnera is successful nowadays because it undergoes a transition to a stabilized therapeutic whose formulation overcomes the metabolic shortcoming of earlier studies [7, 2].

2.3 Modern Validation and the Transition to Small-Molecule therapeutics

Research conducted in our time using historical values as a start has an effect by diminishing the expression of NF-κB and COX-2. As such it reduces the production of a prostaglandin and thus lessens the effect of menstrual pain [1, 8]. Evidence indicates that Allicin prevents systemic inflammation caused by these inflammatory agents, which gives one reason for its effect of reducing pelvic discomfort as well as menstrual cramps [8, 9].

To solve stability and inconsistent outcome issues, scientists are focusing on small molecule therapeutics[7]. It is believed that small-molecule therapeutics are the opposite of traditional large-cell therapeutics. Through modification of the lipid bilayer, thereby disturbing the structures of the lipid membrane, their penetration get enhanced.

Allicin in vivo stability can be enhanced using more sophisticated formulation strategies such as Lecithin-chitosan nanoparticles, nanoemulsions, and more for eight to twelve hours and a reasonable accumulation in ovarian and tumour tissue [7].  As a result of these developments, Allicin activates NRF2 cells which explains its genoprotective ability mechanistically as in the protection of the ovarian follicles and of the endometrial cells against oxidative damage [2 , 9].

2.3. Molecular Mechanisms: The Dual-Action Framework

According to a publication, allicin has a curative effect in bad tissues while ensuring stabilization and protection against genetic damage to healthy cells. Using a dual approach, oncological disease is treated while ensuring reproductive health.

2.3.1 Targeted Apoptosis in Pathological Tissues

Allicin is able to initiate programmed cell death in cancerous cells via the depolarization of the mitochondria. This also holds true for tissues with pathologically rapid growth [9]. The sulphur-containing moiety of allicin reacts with thiol sites on VDACs, restoring mitochondrial membrane potential and enabling cytochrome c to leak into the cytosol.

As a result, the apoptosome is activated which activates caspase-9 and caspase-3/7 pathway [9]. In cervical cancer (HeLa) cells, Allicin at a concentration of 50 ???????? was found to open the mitochondrial permeability transition pore (mPTP) for a period of up to six hours and achieve 50% apoptosis [10]. When Allicin interacts with sulfhydryl groups, it causes the production of high levels of ROS (reactive oxygen species) to attack cardiolipin molecules which occurs due to loss of membrane potential [ 1 and 9]. These mechanisms are quite relevant regarding reproductive health. For example, Allicin treatment reduces rodent endometrial thickness by 40%, explaining the 86% reduction of heavy menstrual bleeding in the MEnera trial [11, 9].

2.3.2 Genomic Stability and NRF2-Mediated Defense

Although it induces cell death in diseased cells, Allicin has been shown to protect the healthy genome by destroying free radicals and encouraging DNA repair [8, 3]. The sulfur-containing groups present in Allicin are capable of direct neutralization of •OH and ONOO– and preventing oxidative DNA damage [8]. Allicin controls the NRF2 cellular defense system owing to its mechanism of activation. This increases the nuclear translocation of NRF2 in human granulosa cells by three-fold and leads to increased expression of antioxidant genes such as glutathione peroxidase, and the DNA repair enzyme OGG1 [3]. Allicin decreases 8-hydroxy-2'-deoxyguanosine (8-OHdG) markers of oxidative DNA damage by 45% in humans [3]. In addition, the arrival of RAD51 proteins to double-strand break sites leads to a 30% speed increase in repair processes that improve genomic stability and oocyte quality [8].

3. METHODOLOGY: MEnera TRIAL

The MEnera trial is a controlled, age-stratified clinical study of Allicin-based small-molecule therapeutics for reproductive pathologies and genomic instability [1, 2]. The findings of the study utilized a two-pronged mechanistic approach – inducing apoptosis at the target disease site and stabilizing the healthy genomic structure [2, 3].

3.1 Ethical Oversight and Study Standards

The FDA, which reported last December, listed Allicin as a monograph OTC drug that was evaluated through clinical trial and monitoring.  The eventual therapeutic activity was determined by the clinical observations and molecular evidence brought together in the study design [5]. To ensure trial is clinically rigorous, as per internationally accepted ethical standards for precision medicine models, it had institutional oversight and IRB approved. Every one of the participants got detailed information on small-molecule therapeutic[3] with genoprotective and apoptogenic properties (i.e., a compound with the ability to protect DNA), and everyone gave his/her informed consent in writing.

3.2 Participant Selection and Sample Size Justification

The study included females with clinical reproductive disorders, 50 with PCOS (Polycystic ovary syndrome) and 30 with endometriosis and 14 with menorrhagia. In order to obtain statistically relevant results, a power analysis justified a sample size of n=80, which aimed at achieving 80% power to trace a large effect size (Cohen’s d≥0.8). The pilot studies were used to calculate E and n taking a0=0.05.

3.3 Cohort Stratification

In an effort to assess how the baseline oxidative stress and physiological changes occurring due to the ageing process impacted the efficacy of the drug, the three cohorts were stratified [1]. Group A (n=20) constituted the 21–40 years age group possessing pretrial Antral Follicle Count (AFC) of 15 and baseline DNA damage lower [1]. Group B (n = 20) were 41-65-aged participants with physiological warning signs of decreased ovarian reserve, such as a pre-trial Anti-Müllerian Hormone (AMH) level of 0.8 ng/mL and a high oxidative stress burden [1, 7]. Group C (n=40) was used as a control that received an inert placebo. The coordination of treat and placebo groups helped establish the biopharmaceutical impact against the natural disease state, and if effective confirm the safety of the product [1].

3.4 Small-Molecule Therapeutic Intervention

The purpose of the MEnera trial is to test and evaluate the clinical efficacy of MEnera small-molecule therapeutics which uses Allicin root as its primary active ingredient [12]. The formulation was chosen for its superior bioactivity and ability to penetrate cells superior to  normal monoclonal antibodies despite its low molecular weight [5, 6]. In order to overcome the natural metabolic instability of Allicin (with a physiological half-life of less than 60 minutes), advanced biopharmaceutical stabilization was used in the formulation [2]. The participants were administered the drug in non-enteric coated capsules once daily to ensure rapid absorption in the intestine [11]. The delivery method was verified to maintain systemic plasma concentration at above 10 μM for a longer duration of 8 hours [13].

Fig. 1. Tumor Cell Apoptosis Induced by Allicin component in MEnera

This mechanism shows the role of Allicin in inducing the death of tumor cells by blocking the PIP3/AKT/mTOR survival axis [8]. The main reason for the bioactivity is due to upregulation of miR-383-5p and subsequent modulation of ERBB4 [8]. The signaling that causes cell death (apoptosis) in the tumor-associated macrophages (TAMs) is induced by granulocytes. This is further amplified by a crosstalk between granulocytes and TAMs leading to a decrease in the viability of the pathological cells [8].

3.5 Clinical and Molecular Endpoints

Evaluating therapeutic success involves integrating multiple symptomatic, cellular and genomic data points  [1]. The criteria for success was having uniform cycles (25-35-day range) as tracked over a period of 90 days and resumption of normal LH pulsations  [1]. To quantify menorrhagia, it was important to assess the gross blood loss. Clinical success was defined as volumes of less than 80 mL per cycle with an 86% reduction of hyperplastic tissue being the target as visually documented in Figure 2 [1, 3]. The primary method of analysis to study genomic stability uses the micronucleus frequency assay on PBMCs in order to detect DNA damage [1, 2]. Specific oxidative DNA damage was measured by detection of 8-hydroxy-2'-deoxyguanosine (8-OHdG) in the follicular fluid[1]. At last, the normalization of endocrine cycles was confirmed based on FSH and LH gonadotropins, a measure of hormonal pulsatility supported by the molecular apoptotic signaling illustrated in Figure 1 [1, 11].

Fig. 2. Diminished Endometrial Hyperplasia following 90 days MEnera Treatment

Clinical findings show a visible 86% reduction in hyperplastic tissue thickness when treated with stabilized Small-Molecule therapeutics [1, 3]. Throughout the 90-day trial period, the progressive thinning of the endometrial lining is directly associated with the return of normal menstrual cycles with reduced uterine blood loss [1]. The normalization of hormone pulsatility and a reduction in genomic instability markers support successful outcomes in this stratified cohort age group [1].

3.6 Statistical Analysis and Validation

To adhere to standards related to clinical significance and reporting of consistent p-values for statistical analysis of the data collected. The main statistical analysis consisted of a Chi-square test which compared the resolution of symptoms between the treated group and the placebo group. The result was highly significant, p< 0.001. Similarly, the frequency of micronuclei was significantly reduced (p=0.002) due to the Allicin effect in Group A as observed through comparative genomic testing with Group C. The risk reduction modeling of those therapeutic outcomes showed a risk reduction of 4.2 times (95% CI: 2.8–6.1). We adjusted for baseline variables including BMI and previous treatments to ensure that these results were reliable. Cohort adherence was over 90% during the 90-day study period.

4. RESULTS

Results from the MEnera clinical trial showed sharp differences in efficacy stratified by age and the instability of the small-molecule therapeutics.  Observations noted an amplification of symptoms by the drug, and clinical data confirmed this.

4.1 Reproductive Outcomes and Fertility Preservation

Findings from this treatment’s study demonstrate significant age-dependent variation in pregnancy and oxidative stress reduction. Younger group A (21–40 years) achieved a 15% pregnancy (6 pregnancy) and 40% reduction in the follicular fluid marker of oxidative stress 8-hydroxy-2’-deoxyguanosine.  The pregnancy rate in Group B (41-65 years) was 5%, and although oxidative stress was still above younger participants’ level, a birth did occur through the NRF2-mediated oocyte repair mechanism. Additionally, both treatment groups saw a significant improvement in menstrual regulation. Specifically, 78% of patients attained regular cycles at 25-35 day intervals. Furthermore, 85% of participants reported a significant reduction in menorrhagia. Ultimately, Allicin as a primary component in small-molecule therapeutic formulas from plant sources can provide high-efficacy treatments with low systemic toxicity.

4.2 Genomic Stability and Cellular Apoptosis

The molecular study of the formulation (Allicin) was genoprotective as it reduced the frequency of micronuclei in PBMCs (Peripheral Blood Mononuclear Cells) in Group A by 40% compared to placebo group (p=0.002). Clinical assessments showed a regression of 50% of caspase-3 dependent hyperplasia in the endometrial tissues of treated patients. In comparison, the placebo (Group C) showed less than 10% improvement in menopausal symptoms as well as irregular bleeding. It must be emphasized that 90% of subjects in this control (Group C) experienced heavy menstrual bleeding above 80 mL per cycle.

4.3 Statistical Significance

According to the Chi-square (p < 0.001), Group A and Group B improved 80% more than Group C in symptoms. Women who take doses of folate are less likely to experience reproductive disorders.

5. DISCUSSION

Allicin is a strategic entry for the design of precision small-molecule therapeutics considering the convergence of ethnopharmacological data with clinical evidence [8, 9]. According to the MEnera trial, the compound is effective because of its capacity to modify the cell membrane and activate signalling pathways [1, 10].

5.1 Translational Oncology Applications

Cancer chemotherapy effectiveness can be enhanced by allicin along with systemic toxicity attenuation. Hence it can be useful.

• Chemosensitivity: Allicin can inhibit drug transport pathways, which reduces IC50 by 70% and overcomes paclitaxel resistance of ovarian cancer cells [1, 11].
• Nephrotoxicity Reduction: Allicin curbs the H2AX protein phosphorylation in renal cells by 60% when used with cisplatin that lowers the nephrotoxicity of cisplatin by 50% [1,12].
• Apoptotic Induction: The compound opens the mitochondrial permeability transition pore (mPTP) [1, 3], thereby activating the intrinsic and extrinsic apoptotic pathways in cancer cells.

5.2 Reproductive Health and Age-Related Risks

Studies have shown that Allicin can treat endometrial hyperplasia but besides oxidative damage limiting its potential, it is unable to sustain genomic stability in older age groups [1, 14]. The findings showed that the members of group B experienced a low dropping micronuclei percentage of 20% that caused 50% miscarriage due to aneuploidy. Consequently, future protocols should study Allicin with coenzyme Q10 to enhance mitochondria functioning and thermoregulation of hypothalamus.

6. CONCLUSION

The MEnera trial supports the view that Allicin (the active molecule of MEnera) is a fundamental candidate for the development of oncological and reproductive medicine. By providing a mechanistic framework for genomic stabilization and targeted apoptosis, the research bridges historical ethnopharmacology and evidence-based therapeutics. As per the revealed evidence from the study, Allicin countered chromosomal aberration with the aid of activating NRF2 cellular defence system whereby mushrooming of ROS was impeded resulting in a significant therapeutic effect in ageing and chemotherapy resistance.

The key findings of this study provide scientific support for the two therapeutic properties of Allicin. 80% improvement in all clinical symptoms across a wide range of reproductive disorders including PCOS, and endometriosis. The success rate of getting pregnant was found to be significantly affected by demographic parameters. When participant cohorts were divided between 21-40 years and 40-65 years of age, then it was observed that the first one managed to achieve a 15% getting pregnant success rate. On the other hand, the 40-65 year cohort only achieved the rate of 5%. Thus, emphasizing the importance of age-stratified therapeutic protocols in precision medicine. The targeted destruction of hyperplastic endometrial cells complemented the genoprotective integrity of the formulation under scrutiny. Furthermore, menorrhagia symptoms were reduced by 86% which affirmed the effector’s capacity to restore uterine homeostasis. In the end, this data validate Allicin as a bona fide precision health platform demonstrating that plant-derived small molecule therapeutics can provide high-efficacy interventions with low systemic toxicity.

7. FUTURE PERSPECTIVES

The following research priorities have been outlined in order to implement the MEnera trial results into widespread clinical practice worldwide.

7.1 Phase II and III Clinical Expansion

Future Phase II and III trials of MEnera should broaden study populations to include ethnic minorities and those with comorbidities [8]. These studies are essential for determining universal therapeutic outcomes and assessing the long-term epigenetic safety during pregnancy to reduce transplacental risks [9].

7.2 Combinatorial Small-Molecule Strategies

There is an urgent requirement to assess Allicin together with other antioxidants and mitochondrial boosters [10]. In a study with women over forty undergoing assisted reproductive technology [11], the synergistic use of Allicin and Coenzyme Q10 has been observed to remedy age-related chromosomal malformations and improved oocyte viability in persons with an AMH below 1 ng/mL. Recommended Phase III trials are accordant.

7.3 Formulation and Delivery Innovation

New approaches need to be developed by scientists to improve the bioavailability and plasma stability of Allicin [12]. Ongoing studies on microfluidic synthesis and folate-conjugated nanoparticles are being carried out to make this drug more accessible in ovarian and tumor tissues, thus extending its half-life beyond one hour [3].

7.4 Precision Biomarker Integration

Biomarkers, mainly oxidative stress indices as well as polymorphisms of NRF2,  help stratify the patients [14]. Personalized dose regimens founded in biomarkers will ensure oncology and reproductive medicine are regulated by physiology [14].

REFERENCES

1. Catanzaro E, Canistro D, Pellicioni V, Vivarelli F, Fimognari C. Anticancer potential of allicin: a review. Pharmacol Res. 2022;177:106118. doi:10.1016/j.phrs.2022.106118.
2. Li J, Xu C, Liu Q. Roles of NRF2 in DNA damage repair. Cell Oncol (Dordr). 2023 Dec;46(6):1577-1593. doi: 10.1007/s13402-023-00834-5.
3. BioAgilytix. Small molecule bioanalysis [Internet]. Durham (NC): BioAgilytix Labs, LLC; 2023 [cited 2026 Jan 12]. Available from: https://www.bioagilytix.com/solutions/modalities/small-molecule-bioanalysis/
4. Grigorian N, Baumrucker SJ. Aromatase inhibitor?associated musculoskeletal pain: an overview of pathophysiology and treatment modalities. SAGE Open Med. 2022;10:20503121221078722.
5. Slusarenko AJ, Patel A, Portz D. Control of plant diseases by natural products: allicin from garlic as a case study. Eur J Plant Pathol. 2008;121(3):313?322.
6. Choudhary N, Gupta MK. A comparative study of perception and practices regarding menstrual hygiene among adolescent girls in urban and rural areas of Jodhpur district, Rajasthan. J Family Med Prim Care. 2019;8(3):875?880. doi:10.4103/jfmpc.jfmpc_69_19.
7. Johnson R, et al. Small molecule pharmacology insights. Pharmacol Rev. 2023;75(2):210?225.
8. Kim H, et al. Age?stratified ovarian reserve and oxidative stress. Fertil Steril. 2023;119(5):789?800.
9. Kumar S, et al. Anti?inflammatory and antioxidant properties of Piper species: a perspective from screening to molecular mechanisms. Curr Top Med Chem. 2015;15(9):886?893.
10. Li C, Jing H, Ma G, Liang P. Allicin induces apoptosis through activation of both intrinsic and extrinsic pathways in glioma cells. Mol Med Rep. 2018;17(4):5976?5981.
11. Li Y, et al. Allicin's role in apoptosis. J Cell Biochem. 2021;122(9):1023?1035.
12. Nasim N, Sandeep IS, Mohanty S. Plant?derived natural products for drug discovery: current approaches and prospects. Nucleus. 2022;65(3):399?411.
13. Nguyen T, et al. Small molecule development in cancer therapy. Cancer Chemother Pharmacol. 2022;89(4):567?579.
14. Wang Q, et al. Natural products in precision medicine. Nat Rev Drug Discov. 2022;21(12):899?917.